AstraZeneca Looks to Add to Small Group of Wilson Disease Drugs

An experimental AstraZeneca drug for Wilson disease hit the mark in a Phase III study in which the drug, ALXN1840, was able to mobilize copper three times greater than standard-of-care.

Related Keywords

London ,City Of ,United Kingdom ,United States ,Marc Dunoyer ,Astrazeneca ,European Union For Wilson ,Drug Administration ,International Liver Congress ,Wilson Disease Treatment Mobilizes Copper ,Liver Congress ,Orphan Drug Designation ,European Union ,Resume ,Careers ,Strazeneca Looks To Add Small Group Of Wilson Disease Drugs ,Iospace ,Advice ,